Oncology Central

IL-6 as a potential biomarker in lung cancer


Lung cancer is the leading cause of cancer-related deaths worldwide. Approximately 1.6 million new cases of lung cancer are diagnosed each year, and 1.4 million deaths are attributed to this disease. At the time of diagnosis, most lung cancer patients are in the advanced stages. Compared with supportive care only, systemic chemotherapy provides survival benefits for advanced non-small-cell lung cancer (NSCLC).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.